Bio-Techne (TECH) Cash & Equivalents (2009 - 2026)

Bio-Techne's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $209.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 49.16% year-over-year to $209.8 million in Q1 2026; TTM through Mar 2026 was $209.8 million, a 49.16% increase from a year earlier, with the FY2025 full-year figure at $162.2 million, up 6.85% from the prior year.
• Cash & Equivalents advanced to $209.8 million in Q1 2026 per TECH's latest filing, from $172.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $209.8 million in Q1 2026 and bottomed at $127.3 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $162.2 million (2025), against an average of $161.0 million.
• Across the five-year window, Cash & Equivalents slipped 22.7% in 2025 and jumped 49.16% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $164.7 million in 2022, then declined by 20.98% to $130.1 million in 2023, then surged by 36.44% to $177.5 million in 2024, then dropped by 2.63% to $172.9 million in 2025, then gained by 21.37% to $209.8 million in 2026.
• Per Business Quant, the three latest TECH Cash & Equivalents figures stand at $209.8 million (Q1 2026), $172.9 million (Q4 2025), and $145.0 million (Q3 2025).